A new non-addictive treatment for eye pain
Official title: Topical Neurokinin-1 Receptor Antagonist as an Effective Non-addictive Analgesic for Ocular Pain
Funded at Schepens Eye Research Institute · NIH-10946971 · Data updated 2026-11-12
This study is looking at a new eye cream that could help relieve chronic eye pain, like from dry eyes or after surgery, without the risk of addiction that comes with regular painkillers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Schepens Eye Research Institute NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 5, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,559,917 |
| NIH project number | 1R61NS131303-01A1 |
| Project ID | NIH-10946971 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals experiencing chronic ocular pain, particularly those with conditions like dry eyes or following corneal injuries.
✕Less likely to help
Patients with acute ocular injuries or those not experiencing chronic pain may not benefit from this research.
What this research studies
This research investigates a topical medication that blocks a specific receptor involved in pain signaling in the eye. By targeting the neurokinin-1 receptor, the study aims to reduce ocular pain without the risk of addiction associated with traditional pain medications. The approach involves understanding the neuro-immune interactions at the ocular surface and how they contribute to pain and inflammation. Patients with chronic ocular pain, such as those suffering from dry eyes or post-surgical pain, may find this treatment beneficial.
Why it matters
Potential benefit: If successful, this research could provide a safe and effective pain relief option for patients suffering from ocular pain.
How similar studies have gone: Previous research has shown promise in targeting the neurokinin-1 receptor for pain management, indicating potential success for this approach.
Where this research is happening
-
Schepens Eye Research Institute
Boston, United States Active
Researchers
- Principal investigator: Dana, Reza — Schepens Eye Research Institute
- Study coordinator: Dana, Reza
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.